Lasmiditan
Lasmiditan is a prescription migraine treatment used in adults to relieve migraine headaches — with or without aura — when they occur.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Lasmiditan: Patient Information Guide
A plain-language walkthrough of Lasmiditan — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Lasmiditan is used to treat migraine attacks when they happen — not to prevent them.
- Reyvow (lasmiditan) oral tablet is FDA-approved for the acute treatment of migraine with or without aura in adults.
- It is taken at the start of a migraine attack, as needed.
- Reyvow is not approved for preventive (daily) migraine therapy.
⚙️How it works▾
Lasmiditan targets a specific serotonin receptor in the brain called the 5-HT1F receptor. By activating this receptor, lasmiditan is thought to quiet the pain signals that drive a migraine attack. The precise chain of events is still being studied, but this targeted approach allows lasmiditan to work without constricting blood vessels the way older migraine drugs (like triptans) do.
💊How it's taken▾
Reyvow tablets are taken by mouth — with or without food — at the start of a migraine. Only one dose should be taken within any 24-hour window. Swallow the tablet whole; splitting, crushing, or chewing it is not appropriate.
- A second dose for the same migraine attack has not been shown to provide additional benefit.
- The safety of treating more than about 4 migraine attacks per month has not been established.
- Always follow your prescriber's instructions for the right dose for you.
🤒Side effects — in detail▾
The most common side effects reported with Reyvow include:
- Dizziness — the most frequently reported side effect, and the top reason people stopped taking it in long-term studies
- Sedation (drowsiness/sleepiness)
- Fatigue (tiredness, weakness)
- Paresthesia — tingling or numbness, sometimes affecting the mouth
- Nausea and/or vomiting
- Muscle weakness
Less common but serious reactions include serotonin syndrome (see warnings), allergic reactions such as rash or swelling, heart rate decreases, and blood pressure changes. Stop Reyvow and get medical help right away if you develop signs of a severe reaction.
⚠️Warnings & precautions▾
- Driving impairment: Reyvow significantly impairs driving ability — even at the lowest dose. Do not drive or operate machinery for at least 8 hours after each dose. You may feel less impaired than you actually are.
- Serotonin syndrome: A potentially life-threatening buildup of serotonin can occur, especially when Reyvow is combined with other serotonin-raising drugs. Symptoms include agitation, hallucinations, rapid heartbeat, high fever, and muscle twitching. Stop Reyvow and seek emergency care immediately if these develop.
- CNS depression: Reyvow can cause significant drowsiness and cognitive impairment. Combining it with alcohol or other sedating medications makes this worse.
- Medication overuse headache: Using acute migraine treatments too often (10 or more days per month) can cause headaches to become more frequent. If this seems to be happening, talk to your doctor.
- Heart rate and blood pressure changes: Reyvow can lower heart rate and temporarily raise blood pressure, particularly in older adults. Your doctor may want to monitor these if you take other medications that affect heart rate.
🔀What it interacts with▾
Reyvow has several important drug and substance interactions to be aware of:
- Alcohol and CNS depressants (sedatives, sleep aids, anti-anxiety medications): Increase drowsiness and impairment — use with great caution or avoid together.
- Serotonin-raising drugs (SSRIs, SNRIs, tricyclic antidepressants, MAO inhibitors, trazodone, dextromethorphan, St. John's Wort): Raise the risk of serotonin syndrome — a potentially dangerous condition.
- Heart rate-lowering medications (e.g., beta-blockers like propranolol): Reyvow can further reduce heart rate when combined with these drugs, which may be a concern for some people.
- Digoxin and similar sensitive drugs (P-gp transporter substrates): Reyvow can increase their levels in the blood, raising the risk of serious toxicity — co-administration is not recommended.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Pregnancy: Animal studies suggest lasmiditan may harm a developing baby. A pregnancy registry exists for women exposed to Reyvow during pregnancy (1-833-464-4724). Discuss the risks with your doctor.
- Breastfeeding: It is not known whether lasmiditan passes into human breast milk. Weigh the benefits of breastfeeding against potential risks with your doctor.
- Children: Safety and effectiveness in patients under 18 have not been established. Reyvow is not approved for pediatric use.
- Older adults (65+): Dizziness occurs more often in older patients, and blood pressure increases can be more pronounced. Dose selection should be cautious.
- Severe liver disease (Child-Pugh C): Reyvow has not been studied in people with severe hepatic impairment and is not recommended for them.
- Driving restrictions: If you cannot reliably avoid driving or using machinery for 8 hours after a dose, Reyvow may not be suitable for you.
- Heart rate concerns: Tell your doctor if you take medications that lower heart rate — Reyvow can add to that effect.
📡Pharmacodynamics — effects in the body▾
Reyvow does not significantly affect the heart's electrical system (specifically the QTc interval — a measure of heart rhythm) even at twice the maximum recommended daily dose. It is associated with modest decreases in heart rate (around 5 to 10 beats per minute) and can temporarily raise blood pressure slightly, particularly in older adults, within the first hour after a dose. These changes generally resolve within 2 hours.
🔬Pharmacokinetics — how your body processes it▾
After swallowing a Reyvow tablet, lasmiditan is rapidly absorbed into the bloodstream — reaching peak levels in about 1.8 hours on average. Eating a high-fat meal slightly increases the amount absorbed and delays peak levels by about an hour, but this difference is not considered clinically meaningful. The drug is broken down mainly by the liver (and to some extent elsewhere in the body) through processes that do not involve the major CYP450 enzyme system, which means fewer drug interactions of that type. Lasmiditan is cleared from the body with a half-life of roughly 5.7 hours, and it does not build up with repeated daily use. Only about 3% of the drug leaves the body unchanged in urine — most is excreted as inactive breakdown products.
📦How to store it▾
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) .
📄 Written from Lasmiditan’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Lasmiditan
110 supplements and herbal products have documented interactions with Lasmiditan in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 8
- Moderate · 87
- Minor · 15
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Lasmiditan — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is Reyvow supposed to do — will it stop my migraine completely? ▾
Why can't I drive for 8 hours after taking it? I only feel a little tired. ▾
I take an antidepressant — is it safe to use Reyvow? ▾
Can I drink alcohol when I take Reyvow? ▾
Is it safe to take Reyvow if I'm pregnant or trying to get pregnant? ▾
How often can I take Reyvow? I get migraines all the time. ▾
Is Lasmiditan available over the counter? ▾
Is Lasmiditan a controlled substance? ▾
When was Lasmiditan first available? ▾
Who makes Lasmiditan? ▾
💬 Answers drafted from Lasmiditan’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Lasmiditan comes
Lasmiditan is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Reyvow tablets are used for the acute (as-needed) treatment of migraine with or without aura in adults.
- Reyvow tablets are not used for daily preventive migraine therapy.
- Reyvow tablets are taken by mouth with or without food.
- Reyvow tablets must be swallowed whole — do not split, crush, or chew.
- Reyvow: take no more than one dose in any 24-hour period.
- Reyvow: do not drive or use machinery for at least 8 hours after taking a tablet.
📊 Lasmiditan across the U.S. market
How Lasmiditan appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (3) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Lasmiditan is used
A general measure of how commonly Lasmiditan is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Lasmiditan is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Lasmiditan prescribed? Of the 1,596 medications we measure, Lasmiditan ranks #1,022 by Medicaid prescriptions — more than 36% of them.
Utilization by Lasmiditan product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
lasmiditan 100 MG Oral Tablet Most dispensed
Summed across the 1 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2256937
lasmiditan 50 MG Oral Tablet
Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2256945
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Lasmiditan, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 9 listed Lasmiditan NDCs with Medicaid activity.
🔍 Compare Lasmiditan products
A representative set of FDA-listed product records for Lasmiditan — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 50 mg | Oral | Eli Lilly and Company × 3 listings | NDA | View NDC → |
| 100 mg | Oral | Eli Lilly and Company × 3 listings | NDA | View NDC → |
| 50 mg | — | Lilly del Caribe, Inc. × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 100 mg | — | Lilly del Caribe, Inc. × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 💊Bulk drug substance | ||||
| 1 kg/kg | — | Eli Lilly Kinsale Limited × 3 listings | BULK INGREDIENT | View NDC → |
Showing 13 of 13 products — FDA National Drug Code Directory. See every product, package size and price: browse all 13 Lasmiditan NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Lasmiditan — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Lasmiditan in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Lasmiditan went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2256930 1 dose form · 2 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 2256936In current FDA listings
Look up RxCUI 2256930 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Lasmiditan is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Lasmiditan belongs to the Selective serotonin (5HT1) agonists class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Eli Lilly and Company is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.